

Special Issue

Recent Advances and Strategies for the Management of CIN and HPV Eradication Strategies for the Prevention of Uterine Cervical Cancer

Message from the Guest Editor

Managing cervical intraepithelial neoplasia (CIN) involves both treatment and follow-up, with HPV eradication strategies focused on preventing future infections through vaccination and early detection by regular screening. We invite you to submit research to this Special Issue titled “Recent Advances and Strategies for the Management of CIN and HPV Eradication Strategies for the Prevention of Uterine Cervical Cancer”, exploring the central theme of preventing uterine cervical cancer, divided into primary and secondary prevention. Primary prevention focuses on the use of HPV vaccines, while secondary prevention involves the diagnosis and management of CIN. We invite manuscripts related to vaccine trials (both preclinical and clinical) and strategies for developing more effective HPV vaccines. Our objective is to compile a range of research addressing the various aspects of HPV that could contribute to more effective strategies for eradicating HPV infection. Potential research areas include, but are not limited to, the following: Diagnosis of CIN; Gynecologic and obstetric risks; Therapeutic effects of treatment.

Guest Editor

Dr. Masaru Sakamoto

1. Department of Gynecology, Sasaki Foundation Kyoundo Hospital, Tokyo 101-0062, Japan
2. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan

Deadline for manuscript submissions

30 April 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/238178

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).